id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-337010-dgy7qbl5	Tomazini, B. M.	COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial.	2020-06-26		.txt	text/plain	5118	313	48	We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult patients with moderate or severe ARDS due to confirmed or probable COVID-19. METHODS: This is a pragmatic, prospective, randomized, stratified, multicenter, open-label, controlled trial including 350 patients with early-onset (less than 48h before randomization) moderate or severe ARDS, defined by the Berlin criteria, due to COVID-19. Therefore, we propose a pragmatic, randomized, open-label, controlled clinical trial, comparing standard treatment versus standard treatment added to early administration of dexamethasone for 10 days in patients with moderate and severe ARDS due to COVID-19. Our primary objective is to evaluate the effectiveness of early intravenous (IV) dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult patients with moderate or severe ARDS due to confirmed or probable COVID-19.	./cache/cord-337010-dgy7qbl5.txt	./txt/cord-337010-dgy7qbl5.txt